McKesson’s Practice Insights Keeps QCDR Status for 10th Year, Expands Oncology Measures
Event summary
- McKesson’s Practice Insights designated as a 2026 Qualified Clinical Data Registry (QCDR) by CMS for the 10th consecutive year.
- Tool collects and reports clinical data for clinicians using IKnowMed® EHR, reducing administrative burdens.
- Nine oncology-specific QCDR measures, including seven developed with The US Oncology Network and two with ASCO.
- New patient-reported outcome measure tracks distress screening and follow-up interventions.
- Two Practice Insights measures retained in 2026 Advancing Cancer Care MIPS Value Pathways.
The big picture
McKesson’s continued QCDR designation underscores its commitment to oncology-focused quality improvement, aligning with broader industry shifts toward value-based care. The expansion of oncology-specific measures and the inclusion of patient-reported outcomes reflect a strategic focus on enhancing care delivery and operational efficiency for community oncology practices. With a decade of consecutive approvals, McKesson solidifies its role as a key player in healthcare IT and specialty pharmacy services.
What we're watching
- Regulatory Alignment
- How McKesson will leverage this designation to expand its footprint in value-based care programs.
- Oncology Focus
- Whether the new patient-reported outcome measure will drive meaningful improvements in psychosocial care.
- Competitive Positioning
- The pace at which McKesson can integrate these measures into broader oncology practice management solutions.
Our editorial coverage:
Related topics